Melinta Therapeutics, Inc. (NASDAQ:MLNT)

7.45
Delayed Data
As of 4:00pm ET
 0.00 / 0.00%
Today’s Change
6.50
Today|||52-Week Range
24.25
-52.85%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$421.3M

Company Description

Melinta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the discover, development and commercialization of antibiotics. Its product, Baxbela, is used in the treatment of acute bacterial skin and skin structure infections. The company was founded by William L. Jorgensen, Peter Moore, and Thomas A. Steitz in October 2000 is headquartered in New Haven, CT.

Contact Information

Melinta Therapeutics, Inc.
300 George Street
New Haven Connecticut 06511
P:(312) 767-0291
Investor Relations:

Employees

Shareholders

Mutual fund holders9.73%
Other institutional16.95%
Individual stakeholders--

Top Executives

Daniel Mark WechslerPresident, Chief Executive Officer & Director
Paul EstremCFO, Secretary & Principal Accounting Officer
Erin M. DuffyChief Scientific Officer & Executive VP
Sue CammarataChief Medical Officer & Executive Vice President
Kate FarringtonChief Compliance Officer & Vice President